Endonovo Therapeutics Inc (ENDV)

[sello]

Definitely a good sign when the main executives believe in the future of the company enough to defer their pay, and despite lack of compensation continue to buy shares on a daily basis, in Mann's case.

From 10-q

Two executive officers and the operations manager of the Company have agreed to defer their compensation until cash flow improves. As of March 31, 2017 and December 31, 2016, the balance of their deferred compensation is approximately $1,857,998 and $1,861,327, respectively.